Posted on Apr 10th 2018
Multiple cellular pathways can lead to acquired resistance to ALK inhibitors. A common pathway is activation of alternate kinase pathways, including EGFR, KIT, SRC, and IGF1R to maintain activation of downstream ERK and/or PI3K-AKT signaling. Addition of inhibitors to these pathways is a viable response, but not optimal due to the presence of multiple alternatives. Dardaei and co-workers have discovered that SHP2, a nonreceptor tyrosine phosphatase, acts as a common targetable resistance node. Treatment of ALK-resistant patient-derived cells with the selective SHP2 inhibitor, SHP099, combined with an ALK inhibitor restored sensitivity via suppression of ERK1/2 reactivation. Focus Biomolecules has high quality SHP099 in stock at the best price on the market.
Focus Biomolecules will be at booth #1039 with the latest cutting edge small molecules for cancer research. Stop by and see the newest chemical tools for research in Cancer Cell Metabolism, Epigenetics, PARP, Kinases, Programmed Cell Death, Autophagy, and much more. We have gifts for everyone who stops by - see you there!
Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone receptors that are critical components of the circadian clock, the body's mechanism for establishing daily rhythms in cellular proliferation, metabolism, and other essential processes. Dysregulation of this system is [...]